Navigation Links
RRD Selected as Development Partner for NIH Therapeutics for Rare and Neglected Diseases Program
Date:1/24/2011

ROCKVILLE, Md., Jan. 24, 2011 /PRNewswire/ -- RRD International, a strategy-driven biotech and pharmaceutical product development company, announced today that it has entered into a partnership with the National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program as a regulatory support and development partner.

The RRD and TRND partnership will focus on two rare disease drug development projects: Hereditary Inclusion Body Myopathy (HIBM), a rare adult-onset neuromuscular disorder and Niemann Pick type C1 Disease (NPC1), a rare neurodegenerative genetic disease.  

"We look forward to combining the product development strengths of RRD with the resources of the NIH TRND program to develop important new treatments for these rare diseases," said Charles (Chuck) Finn, Ph.D., President, CEO, and Co-Founder of RRD International.

As a new congressionally mandated program, TRND is designed to advance preclinical and early clinical development of new drugs for rare and neglected diseases. The program also drives forward adoption of new technologies and treatment paradigms which improve product development efficiency for these diseases.  TRND has formed numerous collaborations with researchers from academia and industry to work on specific rare or neglected diseases.  

"TRND has established partnerships with companies and researchers to identify the most promising molecules that may result in new treatments for rare and neglected diseases," said Christopher P. Austin, M.D., director of the NIH TRND effort. "It is important to note that drug development is not a trivial process and the failure rate for any molecule or compound is high."

The program aims to speed development of new drugs that might otherwise be ignored by industry because they are too early in the development process where the failure rates are high or would not be sufficiently profitable. To make a potential compound attrac
'/>"/>

SOURCE RRD International
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
2. CSA Medical Selected to Present at Mid-Atlantic Bio Conference
3. PMC BioTec Selected as a GoingGreen Silicon Valley 100 Winner
4. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
5. Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility
6. Ion Torrent Selected as World Economic Forum Technology Pioneer
7. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
8. Genedata Phylosopher Selected for ERA-NET sncRNA Project
9. NeoStem Selected to Present at American Society for Apheresis
10. DNA Genoteks Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project
11. OrthoAccel Technologies, Inc. Selected to Pitch at the 2010 WBTshowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Oven Industries Inc. announces a new ... 5R6-900 benchtop controller has many outstanding user-friendly benefits. Contained ... into the wall as a self-contained temperature control system, ... makes the device unique, as well as highly convenient ... can also be used universally, which allows the user ...
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific Shore ... based products across a broad range of product ... retained investor relations firm, BlueWater Advisory Group, to ... to trading process, and to direct the company,s ... Matthew Mills , ...
(Date:5/20/2013)... With bed bugs' presence come problems in various terms. ... to be eliminated, one must make sure that the bed ... so to help bed bug sufferers get that done, it ... bugs without using harmful pesticides. In it, the company ... Bug Bully. , According to My Cleaning Products, contrary to ...
(Date:5/20/2013)... 2013   Flexion Therapeutics , Inc. today announced ... to its management team as chief financial officer. ... management experience with biotechnology and medical device companies. ... financial officer for Novavax (NASDAQ: NVAX ) ... $250 million through a combination of investment funding and ...
Breaking Biology Technology:New Laboratory Temperature Controller by Oven Industries 2Pacific Shore Holdings Retains Investor Relations Firm 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2
... Incorporated,(Nasdaq: GPRO ) announced today that the Company ... on Tuesday, September 9,2008 at approximately 2:45 p.m. Eastern ... may be accessed through a link on the investors,section ... be available for 30 days following the event., ...
... during industry-leading event September 10 - 11, ... 2008 ... Plexus Systems, Inc.,provider of Plexus Online on-demand software for the ... 10-11, 2008 at the San Jose McEnery Conference Center, San ...
... The 33rd ESMO Congress,in Stockholm, the premier European ... medical oncologists, as well as a focal point ... The Congress Centre will be the venue for ... discuss critical issues for,European oncology such as cancer ...
Cached Biology Technology:Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference 2Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference 233rd ESMO Congress in Stockholm, 12-16 September 2008 233rd ESMO Congress in Stockholm, 12-16 September 2008 333rd ESMO Congress in Stockholm, 12-16 September 2008 433rd ESMO Congress in Stockholm, 12-16 September 2008 5
(Date:5/20/2013)... - A National Science Foundation (NSF) planning grant will ... (CARD), a joint program of the University of Illinois ... Mass. , "CARD will be devoted to research in ... agricultural products; forestry and paper products; chemical products; textiles; ... professor of food science and human nutrition and the ...
(Date:5/19/2013)... A novel study reports that white men and women ... bunions (hallux valgus) and lesser toe deformities, including hammer ... first to estimate the heritability of foot disorders in ... journal published by Wiley on behalf of the American ... that as many as 60% of older adults have ...
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) explores ... the impact of coffee on autoimmune disease and palliative ... recently has been associated with reduced risk of fibrosis, ... cups of java each month also correlate with lower ... the Mayo Clinic, Rochester, MN, linked coffee consumption with ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Blame your parents for bunion woes 2Coffee consumption associated with reduced risk of autoimmune liver disease 2
... blood clot-dissolving medication that is administered to some patients ... reduce the risk of amputation following severe frostbite, according ... of Surgery, one of the JAMA/Archives journals. , Frostbite ... 25 years, according to background information in the article. ...
... the University of Central Florida is proving promising as ... disease that can cause blindness and affects millions of ... the blood-brain barrier making it an effective non-toxic tool ... with appointments in UCF’s Advanced Materials Processing and Analysis ...
... A major obstacle in the treatment of infections and ... which prevents systemically delivered therapeutic drugs from reaching the ... Infectious Diseases, part of the National Institutes of Health, ... the rabies virus can carry a strip of therapeutic ...
Cached Biology News:Clot-dissolving agent may be beneficial in treatment of severe frostbite 2UCF nanoparticle offers promise for treating glaucoma 2Blood-brain barrier breached by new therapeutic strategy 2
Request Info...
... are functionally defined by their capacity to ... into multiple specialized progenitor cells, which can ... Neural stem cells (NSCs) are capable of ... neurons and oligodendrocytes. During the isolation and ...
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
Anti Human JAM-1, Monoclonal Antibody, Clone M.Ab.F11...
Biology Products: